Isolation and characterization of novel process-related impurities in empagliflozin.
Sign Up to like & getrecommendations! Published in 2021 at "Journal of pharmaceutical and biomedical analysis"
DOI: 10.1016/j.jpba.2021.114001
Abstract: Empagliflozin is an effective sodium glucose cotransporter-2 (SGLT2) inhibitor to improve glycemic control in adults with type 2 diabetes. During the manufacture of empagliflozin, three unknown impurities were discovered in pilot batches ranging from 0.05… read more here.
Keywords: characterization novel; isolation characterization; novel process; related impurities ... See more keywords